Patents
Method of preparing an undifferentiated cell
Patent Number: 7,220,412This patent covers the use of anti-MHC antibodies to induce "retrodifferentiation" of peripheral blood cells into CD34 hematopoietic stem cells. If there is even a shred of evidence that the concepts put forth in this patent are real, then the inventors are sitting on a gold mine. However, with exception to publications in very very low impact journals only by the authors of the patent, we...
Inventors: Abuljadayel; Ilham Saleh (London, GB)
Assignee: Ghazi Jaswinder Dhoot (London, GB)
Date of First Priority Issue: Wednesday January 31st, 1996
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
Patent Number: 7,220,407Subsequent to myocardial infarction, cells of the injured myocardium release a variety of cytokines and mediators that are involved in mobilizing endogenous bone marrow stem cells and inducing their migration to the area of myocardial injury. One cytokine released is G-CSF, which in addition to possessing hematopoietic functions also is a great mobilizer of stem cells. In the current...
Inventors: Mehta; Jayesh (Chicago, IL), Singhal; Seema (Chicago, IL), Davidson; Charles (Winnetka, IL), Beohar; Nirat (Chicago, IL), Bonow; Robert (Glencoe, IL)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 27th, 2003
Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
Patent Number: 7,217,565This patent covers the isolation of neural stem cells, primarily from human fetal origin. These stem cells are purified by 2 steps. First the fetal cells are bound to the antibody 8G1 and then they are further purified for expression of AC133 and 5E12. This patent is similar to several others from the same family such as Patent...
Inventors: Buck; David W. (Eugene, OR), Uchida; Nobuko (Palo Alto, CA), Weissman; Irving (Redwood City, CA)
Assignee: StemCells California, Inc. (Palo Alto, CA)
Date of First Priority Issue: Friday February 12th, 1999
Methods of identifying and isolating stem cells and cancer stem cells
Patent Number: 7,217,568This patent teaches that tumor stem cells can be extracted population of non-stem cells by selecting for the cells which have activation of the transcription factor LEF/TCF and/or the beta.-catenin pathway. This patent essentially takes a pathway that is known to be activated in non-malignant sttem cells and simply applies it to malignant stem cells. Some may argue that in light of KSR v...
Inventors: Jamieson; Catriona Helen M. (Palo Alto, CA), Ailles; Laurie Elizabeth (Stanford, CA), Reya; Tannishtha (Mountain View, CA), Weissman; Irving L. (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Date of First Priority Issue: Friday May 30th, 2003
Clonal cultures of primate embryonic stem cells
Patent Number: 7,217,569This patent covers ways to generate "clonal" embryonic stem cell lines. At face value this specification does not seem to offer anything new in comparison to the previous WARF patents.
Inventors: Thomson; James A (Madison, WI)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday March 9th, 2000
Use of osteopontin for the treatment and/or prevention of neurologic diseases
Patent Number: 7,217,687Osteopontin, is a protein also called cytokine Eta-1, which contains Arg-Gly-Asp-Ser (RGDS) cell-binding sequences. Osteopontin is associated with cancer metastasis, as well as inflammatory immune cell migration, it interacts with alpha(v)beta1, alpha(v)beta3 and alpha(v)beta5 integrins and CD44 receptors. The current patent covers the use of osteopontin and various derivatives for treatment...
Inventors: Boschert; Ursula (Troinex, CH), Feger; Georg (Thoiry, FR), Selvaraju; Raghuram (Vandoeuvres, CH), Bernasconi; Lilia (Perly, CH), Papoian; Ruben (Cincinnati, OH)
Assignee: Applied Research Systems ARS Holding N.V. (Curacao, AN)
Date of First Priority Issue: Thursday May 17th, 2001
Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
Patent Number: 7,217,294This patent covers a method of inducing articular cartilage healing/regeneration through the implantation of acellular matrices that can be used for either delivery of cells or growth factors. The patent is written as one independent claim covering essentially: a)the scaffold; b) a sealant that protects the scaffold from debris; c) the implantation of the scaffold; and d) the deposition of...
Inventors: Kusanagi; Akihiko (Brookline, MA), Tarrant; Laurence J. B. (Northampton, MA), Schmidt; Mary Beth (Pomfret Center, CT)
Assignee: Histogenics Corp. (Northampton, MA)
Date of First Priority Issue: Wednesday August 20th, 2003
Tissue engineered biografts for repair of damaged myocardium
Patent Number: 7,214,371This patent covers various matrices that are seeded with cells in vitro and implanted in vivo into myocardial tissue so as to allow regeneration or healing. The patent uses a porous polysaccharide composition for shaping the matrics since it allows optimal cell viability and differentiation in vitro. The patent also covers embedding of various growth factors and cytokines in the matrix so as...
Inventors: Cohen; Smadar (Beer Sheva, IL), Dar; Ayelet (Rehovot, IL), Etzion; Sharon (Beer Shevea, IL), Perets; Anat (Bet-Shemesh, IL), Shaprut; Sigalit (Beer Sheva, IL), Leor; Jonathan (Gane' Tikva, IL)
Assignee: Ben-Gurion University of the Negev Research & Development Authority (Beer-Sheva, IL)
Date of First Priority Issue: Friday September 1st, 2000
Methods using lineage restricted glial precursors from the central nervous system
Patent Number: 7,214,372Neurodegenerative diseases such as multiple sclerosis cause pathology, in part, through demyelination. Since the myelin sheath acts as an insulator of nerves, when the nerves are demyelinated, they cease proper function. The current patent covers the use of glial restricted precursors, as well as oligodendrocyte differentiated glial restricted precursors, for remyelination of nerves. These...
Inventors: Rao; Mahendra S. (Salt Lake City, UT), Noble; Mark (Brighton, NY), Mayer-Proschel; Margot (Pittsford, NY)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Saturday November 29th, 1997
Liver engrafting cells, assays, and uses thereof
Patent Number: 7,211,404Hepatic diseases are a major scourge on our society. Currently great progress has been made through the use of autologous bone marrow stem cells for treatment of these diseases. In the current patent, a cell that is capable of engrafting in the liver is disclosed. the cell is of hepatic origin and is positive for 5E12 and/or Ep-Cam and/or CD49f and/or E-Cadherin and/or lacking or haveing...
Inventors: Lagasse; Eric (Palo Alto, CA), Austin; Timothy (Morgan Hill, CA)
Assignee: Stem Cells, Inc. (Palo Alto, CA)
Date of First Priority Issue: Thursday June 21st, 2001